Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
Provided By GlobeNewswire
Last update: Dec 20, 2024
NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
Read more at globenewswire.comNASDAQ:GALT (6/20/2025, 12:34:10 PM)
2.5633
-0.73 (-22.09%)
Find more stocks in the Stock Screener
GALT Latest News and Analysis
21 minutes ago - ChartmillThese stocks are moving in today's sessionKeep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
3 days ago - ChartmillThese stocks are moving in today's sessionKeep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
3 days ago - ChartmillWhich stocks are moving on Tuesday?Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
